Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN)
Rovin B, Furie R, Malvar A, Aranow C, Pego-Reigosa J, Zakharova E, Schwarting A, Jones-Leone A, Gilbride J, Ji B, Roth D, Curtis P, van Maurik A. Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN). Journal Of The American Society Of Nephrology 2023, 34: 972-973. DOI: 10.1681/asn.20233411s1972c.Peer-Reviewed Original Research